Paris – May 21, 2025 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced three-year results from the large 445-patient ...
LONDON – September 2, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the INFINITY-SWEDEHEART Randomized Controlled Trial (RCT) comparing ...
MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the first patient has been treated in the BIOADAPTOR randomized ...
Dubai, UAE: – Elixir Medical, a developer of breakthrough cardiovascular technologies with a strong presence in the Middle East market, today announced that the large international randomized ...
MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor ...
Kuwait – Elixir Medical, a developer of advanced systems to treat coronary artery disease, announced the launch of the DynamX™ Coronary Bioadaptor System at centers of excellence in the Middle East.
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES- -Significantly lower ...
(MENAFN- GlobeNewsWire - Nasdaq) Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback